Biotech Values

[iwfal]

The slides in question compared the safety profile of IFN-lambda monotherapy side by side with the safety profile of IFN-alpha plus ribavirin (from separate trials).

I made a similar comment (albeit without the term 'disingenuous') - that they seem to have had a problem similar to mine in finding comparible monotherapy data on platelets and neutrophils. That said, they probably should have caveated it somehow.

PS I have literally no idea how much of the SAEs are caused by IFN-A, how much by ribavirin and how much by synergy. I haven't finished looking yet - but ... .